Table 1.
Bioactivities of cyanobactins produced from cyanobacteria.
| Source Organism | Compound | Bioactivity | References |
|---|---|---|---|
| Lissoclinum patella (Prochloron spp.) | Lissoclinamides 1–3 | Borderline cytotoxicity against L1210 murine leukemia cells (IC50 > 10 µg/mL) | [22] |
| Lissoclinamides 4–6 | Slight cytotoxicity against PS lymphocytic leukemia cells (ID50 = 10, 12 and 6.9 µg/mL for lissoclinamides 4, 5 and 6, respectively) | [22] | |
| Patellamide A | Mild cytotoxicity against L1210 murine leukemia cells (IC50 = 3.9 µg/mL) | [21,57] | |
| Poor cytotoxicity against KB cell line (IC50 = 3000 ng/mL) | |||
| Patellamide B | Mild cytotoxicity against L1210 murine leukemia cells (IC50 = 2.0 µg/mL) | [21,57,59,60] | |
| Poor cytotoxicity against KB cell line (IC50 > 4000 ng/mL) | |||
| General cytotoxicity in NCI’s 60 human tumor cell line panel (Average LC50 = 48 µM) | |||
| Multidrug reversing activity | |||
| Patellamide C | Mild cytotoxicity against L1210 murine leukemia cells (IC50 = 3.2 µg/mL) | [21,57,60] | |
| Poor cytotoxicity against KB cell line (IC50 = 6000 ng/mL) | |||
| Multidrug reversing activity | |||
| Patellamide D | Slight cytotoxicity against PS lymphocytic leukemia cells (ID50 = 11 µg/mL) | [22] | |
| Multidrug reversing activity | |||
| Patellamide E | Weak cytotoxicity against human colon tumor cells (IC50 = 125 µg/mL) | [58] | |
| Patellamide F | General cytotoxicity in NCI’s 60 human tumor cell line panel (Average LC50 = 13 µM) | [59] | |
| Patellin 6 | Moderate cytotoxic against P388, A549, HT29 and CVI cells (Average IC50 = 2 µg/mL) and inhibition of topoisomerase II activity (IC50 = 2.5µg/mL) | [24] | |
| Trunkamide A | Active against P-388 mouse lymphoma, A-549 human lung carcinoma, HT-29 human colon carcinoma (IC50 = 0.5 µg/mL) and MEL-28 human melanoma (IC50 = 1.0 µg/mL) cell lines. | [69] | |
| Ulicyclamide | Poor cytotoxicity against L1210 murine leukemia cells (IC50 = 7.2 µg/mL) | [21] | |
| Ulithiacyclamide | Cytotoxicity against L1210 murine leukemia (IC50 = 0.35 µg/mL) and KB (IC50 = 35 ng/mL) cell lines | [21,57,59] | |
| General cytotoxicity in NCI’s 60 human tumor cell line panel (Average LC50 = 3 µM) | |||
| Ulithiacyclamide B | Cytotoxicity against KB cell line (IC50 = 17 ng/mL) | [57] | |
| Microcystis aeruginosa | Aerucyclamides | Toxic to freshwater crustacean Thamnocephalus platyurus (LC50 = 30.5 µM for aerucyclamide A and LC50 = 33.8 µM for aerucyclamide B) | [29,30,31] |
| Antimalarial (aerucyclamide B presented IC50 = 0.7 µM, aerucyclamide C presented IC50 = 2.3 µM and aerucyclamide D presented IC50 = 6.3 µM) | |||
| Aerucyclamide C—moderate activity against Trypanosoma brucei rhodesiense (IC50 = 9.2 µM) | |||
| No inhibitory activity against HeLa cells and standard antiproliferative, antibacterial and antifungal assays | |||
| Microcystis aeruginosa NIES-298 (freshwater) | Microcyclamide | Slight cytotoxicity against P388 murine leukemia cells (IC50 = 1.2 µg/mL) | [27] |
| Microcystis sp. | Microcyclamide | Microcyclamide MZ602—mild cytotoxicity against Molt4 leukemia cell line (20% cell grow inhibition) and mild inhibition of chymotrypsin (IC50 = 75 µM) | [70] |
| Microcyclamide MZ568—strong cytotoxicity against Molt4 leukemia cell line (36% cell grow inhibition) and no inhibition of serine proteases | |||
| Nostoc spongiaeforme var. tenue (litophytic) | Tenuecyclamide A, C and D | Inhibited division of sea urchin embryos Paracentrotus lividus (ED100 = 108 µM, for tenuecyclamide A, ED100 = 9.0 µM for C and ED100 = 19.1 µM for D). B not tested. | [25] |
| Trichodesmium erythraeum IMS 101 (marine) | Trichamide | No effects found (tested for cytotoxicity, antifungal, antibacterial and antiviral activities) | [28] |